Using Miotic Agents for the Management of Presbyopia
December 05, 2022
Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
Presbyopia
Targeting Pupil Size for Presbyopia Management
December 05, 2022
Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.
Impact of Presbyopia on Mechanism of Ocular Accommodation
November 23, 2022
Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.
Overview of Presbyopia
November 23, 2022
Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.
Ocuphire reaches license agreement for the development and commercialization of Nyxol
November 08, 2022
The deal with FamyGem Life Sciences covers the development and commercialization of Nyxol eye drops for the reversal of mydriasis, presbyopia and night vision issues.
App brings virtual eye care to Bangladesh
October 29, 2022
The EyeBuddy app will bring telehealth to eye doctors in the coming months, connecting patients across Bangladesh with ophthalmologists at a major eye-care hospital.
Eyenovia announces results from VISION-2 study
October 21, 2022
The company noted the phase 3 study looked at MicroLine as a potential on-demand treatment for presbyopia.
Phase 2 INSIGHT study: Improved near vision with 2 drop formulations
October 19, 2022
LENZ Therapeutics has unveiled positive topline data from its INSIGHT study achieved by 2 formulations to treat presbyopia.
Visus Therapeutics CEO announces acquisition of ViewPoint Therapeutics to expand on cataract, presbyopia candidate
September 30, 2022
Ben Bergo, CEO of Visus Therapeutics, announced the acquisition of all patents and other assets of ViewPoint Therapeutics, which will accelerate development of novel alpha-crystallin chaperone compounds as a non-surgical treatment for age-related cataracts.
VIDEO: Drops for presbyopia correction show promise in Phase 3 safety studies
September 20, 2022
At the recent Women in Ophthalmology Summer Symposium, held in Monterey, California, Cathleen M. McCabe, MD, outlined how pilocarpine HCl Ophthalmic Solution 1.25%, the first and only FDA-approved eye drop to treat presbyopia could offer an opportunity for patients looking for spectacle independence.
Advertisement
Advertisement